Jakarta, 31 July 2024 - Based on the Consolidated Financial Statements of PT Enseval Putera Megatrading Tbk and Its Subsidiaries (the Company) dated 30 June 2024 and for the period then ended (Unaudited), the Company hereby informs that in the first half of 2024, the Company's Net Sales recorded IDR 15,609.29 billion, growing by 10.91% compared to the Net Sales in the first half of 2023 which recorded IDR 14,073.28 billion.

The Company's Cost of Goods Sold in the first half of 2024 was recorded at IDR 14,084.71 billion, an increase of 11.33% compared to the first half of 2023 which recorded IDR 12,651.45 billion.

Thus, the Company's Gross Profit recorded IDR 1,524.59 billion in the first half of 2024, growing by 7.23% compared to the Gross Profit in the first half of 2023 which recorded IDR 1,421.83 billion.

In the first half of 2024, the Company's Operating Expenses were recorded at IDR 1,046.22 billion, consisting of Selling Expenses of IDR 906.88 billion and General and Administrative Expenses of IDR 139.34 billion, or an increase of 5.75% compared to the first half of 2023. Thus, the Company recorded an Operating Profit of IDR 478.37 billion, increasing by 10.61% compared to the Operating Profit in the first half of 2023 which recorded IDR 432.48 billion.

The Company's Profit Before Income Tax Expenses in the first half of 2024 was recorded at IDR 473.56 billion, an increase of 6.82% compared to the same period in 2023. The composition of Other Income (Expenses) includes Financial Income of IDR 8.52 billion, Financial Expenses of IDR 10.65 billion, Final Tax Expenses of IDR 2.52 billion, Net profit share in associates of IDR 3.63 billion, Other operating income of IDR 12.79 billion, and Other operating expenses recorded at IDR 16.58 billion.

The Company's Income Tax Expenses in the first half of 2024 were recorded at IDR 107.88 billion, increasing by 10.53% compared to the same period in 2023 which recorded IDR 97.60 billion.

Thus, the Company can record a Profit for the Period of IDR 365.68 billion in the first half of 2024, increasing by 5.77% compared to the same period in 2023 which recorded IDR 345.74 billion.

From the comparison of the Company's Consolidated Financial Position Statements as of 30 June 2024 (Unaudited) with the Company's Consolidated Financial Position Statements as of 31 December 2023 (Audited), the Company's Total Assets increased by 4.40%, from IDR 10.96 trillion to IDR 11.44 trillion. The Company's Total Liabilities increased by 15.46% from IDR 3.66 trillion as of 31 December 2023 to IDR 4.22 trillion in the first half of 2024. Thus, the Company's Total Equity decreased by 1.15% from IDR 7.30 trillion to IDR 7.21 trillion in the first half of 2024.

Performance of Each Division

Currently, the Company has 7 Divisions, consisting of the Consumer Goods Division, Prescription Drugs Division, Over-the-Counter Drugs Division, Raw Materials for Sale Division, Medical Equipment Division, Veterinary Drugs and Livestock Division, and Health Services and Transportation Division.

The detailed performance of each Division within the Company can be described as follows:

• Consumer Goods Division is the division with the largest contribution to total Net Sales, which is 39.72%. In the first half of 2024, this division managed to record Net Sales of IDR 6,200.45 billion, an increase of 5.52% compared to the same period in 2023.
• Prescription Drugs Division provides the second-largest contribution after the Consumer Goods Division with a contribution of 33.23%. Up to the first half of 2024, the Prescription Drugs Division managed to record Net Sales of IDR 5,187.55 billion, growing by 21.36% compared to the same period in 2023.
• Over-the-Counter Drugs Division managed to record Net Sales of IDR 2,251.91 billion in the first half of 2024 with a contribution of 14.43% and an increase of 12.85% compared to the same period in 2023.
• Raw Materials Division recorded Net Sales of IDR 1,179.28 billion in the first half of 2024, a decrease of 2.29% compared to the same period in 2023, and contributed 7.55%.
• Medical Equipment Division contributed 4.67% in the first half of 2024, with recorded Net Sales of IDR 729.20 billion, an increase of 11.79% compared to the same period in 2023.
• Veterinary Drugs and Livestock Division recorded Net Sales of IDR 26.46 billion, an increase of 10.43% compared to the same period in 2023 which recorded IDR 23.96 billion. This division contributed 0.17% to the Company's total Net Sales.
• Health Services and Transportation Division recorded Net Sales of IDR 34.45 billion, a decrease of 21.93% compared to the same period in 2023. This division contributed 0.22%.

About Enseval

Enseval is the largest distribution company in Indonesia that started distribution activities since 1973 and has more than 4,600 employees. Enseval became a public company on 1 August 1994 under the name PT Enseval Putera Megatrading Tbk (IDX: EPMT). Besides distributing products from the Kalbe Group, Enseval has also been trusted by other principals both from within and outside the country. The Company has an extensive distribution network with 3 Distribution Centers located in Jakarta, Cikarang, and Surabaya, and 48 branches spread across the Indonesian archipelago, as well as 23 branches through its subsidiary PT Tri Sapta Jaya. To date, the Company has 9 subsidiaries, operating in the fields of distribution, raw materials, medical equipment, health services, and transportation.